Modulation of Epstein-Barr-Virus (EBV)-Associated Cancers by Co-Infections.

Burkitt’s lymphoma Epstein Barr virus (EBV) Helicobacter pylori Kaposi-sarcoma-associated herpesvirus (KSHV) Plasmodium falciparum human cytomegalovirus (HCMV) human immunodeficiency virus (HIV) human papilloma virus (HPV) malaria primary effusion lymphoma (PEL)

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
07 Dec 2023
Historique:
received: 16 11 2023
revised: 04 12 2023
accepted: 05 12 2023
medline: 23 12 2023
pubmed: 23 12 2023
entrez: 23 12 2023
Statut: epublish

Résumé

The oncogenic and persistent Epstein Barr virus (EBV) is carried by more than 95% of the human adult population. While asymptomatic in most of these, EBV can cause a wide variety of malignancies of lymphoid or epithelial cell origin. Some of these are also associated with co-infections that either increase EBV-induced tumorigenesis or weaken its immune control. The respective pathogens include Kaposi-sarcoma-associated herpesvirus (KSHV),

Identifiants

pubmed: 38136285
pii: cancers15245739
doi: 10.3390/cancers15245739
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Swiss National Science Foundation
ID : 310030_204470/1
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 310030L_197952/1
Pays : Switzerland

Auteurs

Christian Münz (C)

Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland.

Classifications MeSH